Tag: source

VANCOUVER, British Columbia, July 21, 2025 (GLOBE NEWSWIRE) -- ERAG Energie & Rohstoff AG PCC (the “Acquiror), a private investment a private investment holding company incorporated in Liechtenstein, announces that on July 17, 2025, the Acquiror, along with two joint actors HMS Bergbau AG (“HMS”) and LaVo Verwaltungsgesellschaft MBH (“LaVo”), acquired Common Shares of Belmont Resources Inc. (TSX-V: BEA) (the “Issuer”). The Issuer completed a private placement of Common Shares, issuing a total of 26,300,00 shares at a price of $0.045 per share for proceeds of $1,183,500 (the “Private Placement”). Under the Private Placement, the Acquiror purchased 4,000,000 Common Shares, HMS purchased 15,000,000 Common Shares and LaVo purchased 7,300,000 Common Shares.

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Choir Performance and Powerful Tribute Demand Action to Protect Children from Climate-Fueled Disasters

Chicago, Illinois, July 21, 2025 (GLOBE NEWSWIRE) -- RICH Miner officially launched its new DOGE (Dogecoin) cloud mining application, announcing that cloud mining has entered a new era of "low carbon, zero threshold, and daily arrival".

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.